The primary aims of the Hawaii Minority/Underserved NCORP are to build on the accomplishments already made by the Hawai'i MB-CCOP since 1994 and the Hawai'i NCCCP since 2010. As the primary provider of NCI clinical trials and health care delivery research in our state which has a majority of racial/ethnic minority patients, the Hawai'i Minority/Underserved NCORP will continue to provide individuals in their own communities with NCORP studies, thereby contributing to an evidence base that will lead to improved patient outcomes and reduce cancer disparities experienced by the people of Hawai'i and elsewhere. The Hawai'i Minority/Underserved NCORP will continue to use a network of components and subcomponents established through the MB-CCOP and contribute to the administrative and scientific leadership of research bases, as before. The Queen's Medical Center component is a recipient of an NCCCP award which has enabled it to build substantial capacity to conduct cancer care delivery research and a group of investigators who will contribute to scientific and administrative leadership in research bases generating these studies. Participating in NCORP cancer prevention, control, screening/post treatment surveillance, treatment and imaging trials along with health related quality of life and cancer care delivery research, will enable past accomplishments in reducing cancer care disparities to be taken to an even higher level to reduce the burden of cancer for the people of Hawai'i and elsewhere.

Public Health Relevance

The Hawai'i Minority/Underserved NCORP through 1) conducting clinical trial/cancer care delivery research, 2) contributing to NCORP research bases, and 3) contributing Hawaii's multiracial/multiehnic population to a national evidence base, will reduce cancer care disparities and the burden of cancer for the people of Hawai'i and elsewhere.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189804-03
Application #
9114543
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Pearson, Deborah
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Kleckner, Ian R; Kamen, Charles; Gewandter, Jennifer S et al. (2018) Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 26:1019-1028
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952

Showing the most recent 10 out of 17 publications